|Day Low/High||8.35 / 8.77|
|52 Wk Low/High||6.97 / 16.30|
Erin Andrews, host of ABC's Dancing with the Stars, reporter with Fox Sports and cervical cancer survivor, will be a special guest at a forum designed to provide patients and families with an overview of the impact of...
Investors eyeing a purchase of Advaxis Inc stock, but tentative about paying the going market price of $8.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $7.50 strike, which has a bid at the time of this writing of 90 cents.
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, was named to NJBIZ's 2017 Best Places to Work in New Jersey list, as compiled and ranked by the Best Companies Group (BCG).
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 1,212,760 share increase in total short interest for Advaxis Inc , to 10,115,830, an increase of 13.62% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Investors in Advaxis Inc saw new options become available this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADXS options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Advaxis, Inc. saw new options become available this week, for the February 2017 expiration.
Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc.